Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027627 (metastases)
 103,950 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The authors present the experience about modifications of the mammographic data caused by X-ray irradiations which are described in three publications of other authors. Then they mention a first case observed by themselves in 1953 and give a detailed description and documentation of a new observation. In these cases and contrary to the reports of the other authors, a total regression of the tumor shadow in the radiogram was found. The first patient had demonstratable pulmonary metastases already when she was irradiated and the new patient died of cachexia. Before she died, metastases of the vertebral column were demonstrated by radiography which, according to the general and clinical findings, had certainly already existed at the beginning of radiotherapy. It had not been possible to find out what was the nature of pasty swellings lying near the tumor which had not been visible on the radiogram.
 ...
PMID:[Control of the success of radiotherapy in case of mastocarcinomas by means of mammography (author's transl)]. 9 Dec 46

The results of this study concern the comparison of the clinical effects of adriamycin (ADM) or bleomycin (BLM) alone and combined with local hyperthermia on 15 patients with multiple (29) neck node metastases from head and neck cancers. With repeated low fractional daily doses of drug a significant though transient tumor regression was obtained in 2/8 and in 3/6 of the lesions treated with ADM or BLM alone, respectively. When the drugs were combined with 42-43 degrees C hyperthermia, an overall response, either complete or partial, was seen in all the lesions. Complete regression was observed in 38% (3/8) and 43% (3/7) of the lesions treated with ADM or BLM, respectively, combined with heat. At a 4-month follow-up, 33% (2/6) and 40% (2/5) of the same groups of lesions remained still undetectable. These results suggest that the combined treatment of drugs and local hyperthermia can be advantageously employed in clinical practice for treating local tumors, especially recurrences in previously irradiated areas.
 ...
PMID:Enhanced effectiveness of adriamycin and bleomycin combined with local hyperthermia in neck node metastases from head and neck cancers. 9 Dec 51

Patients with metastatic nonseminomatous testicular cancer received an induction regimen consisting of bleomycin in 24-hour infusions and bolus iv doses of vinblastine followed by an Adriamycin and cis-dichlorodiammineplatinum(II) combination. Patients achieving complete remission after one or two cycles of this induction chemotherapy were then randomized to receive either radiotherapy (RT) to the previously involved tumor areas or maintenance chemotherapy (MCT) with CCNU, methotrexate, and vinblastine for 2 years. Among 62 evaluable patients, induction chemotherapy achieved 15 (24%) partial remissions and 35 (56%) complete remissions. Two patients with partial remission and single pulmonary metastases were rendered disease-free by surgical resection of residual tumor. Twenty patients received MCT and 15 received RT. To date, median survival is 10,8+ months in the MCT group with five relapses and 12.5 months in the RT group with two relapses. Toxicity in the induction phase was moderately severe with two drug-related deaths.
 ...
PMID:Treatment of metastatic nonseminomatous testicular cancer: a preliminary report of induction chemotherapy followed by maintenance chemotherapy or radiotherapy. 9 36

Arterial embolization was performed in nine patients with metastases from renal carcinoma who had severe pain resistant to conventional therapy. Patients with metastases in the ilium (four), the lumbosacral spine (one), and the base of the skull (one) experienced pain relief lasting from one to six months. The other three patients, who had metastases in the proximal femur, underwent preoperative embolization to facilitate tumor curettage and internal hip fixation. No significant complications were seen with this therapeutic approach.
 ...
PMID:Arterial occlusion in the management of pain from metastatic renal carcinoma. 9 38

Epithelioid sarcoma of the palm of 7 months' duration was observed in a 30-year-old man. Six months after wide surgical excision there was no evidence of recurrence or metastasis. By light microscopic examination the tumor showed typical nodular arrangement of malignant cells, with necrosis of these cells in the centers of the nodules. Patchy lymphocytic infiltrates were observed at the peripheries of the nodules and also extended in places between the tumor cells. Other types of inflammatory cells were practically absent. By electron microscopic examination it was noted that numerous neoplastic cells formed firm close contacts with lymphocytes. Considerable numbers of neoplastic ells so contacted were damaged or even disintegrated. The damaged tumor cells contained abundant lysosomes. The release of enzymes from these lysosomes in the disintegrating tumor cells might be an important factor underlying the extracellular tissue injury and necrosis so conspicuous in epithelioid sarcoma. The very slow growth of this neoplasm and its slow tendency to metastasize might be related to the high efficacy of lymphocyte-mediated defenses against this tumor.
 ...
PMID:Epithelioid sarcoma: ultrastructural observation of lymphoid cell-induced lysis of tumor cells. 9 47

The treatment results of the Rotterdam working group on esophageal cancer during the period January 1970-January 1978 were assessed. A total number of 328 patients were treated: 230 males and 98 females. Of the 133 patients eligible for a combined treatment modality i.e. preoperative radiotherapy and surgery, 52 showed irresectable or metastatic disease during operation. The five year actuarial survival rate of the 81 patients, in whom curative surgical resection of the tumor was performed, amounted to 21%. Females fared better than males, the five year survivals being 42% and 12% respectively. This female preponderance in survival is partly explained by the considerable postoperative mortality of the male patients: 28% vs 7.4% in females. Patients who received only radiation therapy, whether curative or palliative, had a very bad prognosis. It is concluded that preoperative irradiation followed by surgical removal of the tumor should be performed in all operable-curable patients.
 ...
PMID:Carcinoma of the esophagus: results of treatment. 9 16

Tumor scintigraphic localization of neoplasms can be done in two ways: indirectly and directly. The first method shows alternations of the normal structure of the organ, such as "cold lesions" in liver and thyroid. Abnormalities in function as increased permeability of the blood barrier results from abnormal deposition of the radionuclide in the brain scintigram of a patient with neoplasm. Increased focal areas of uptake of bone-seeking radionuclides are very characteristic of metastases. The direct methods depend on preferential uptake of the radionuclide by the neoplastic tissue resulting from altered metabolism (e.g. Se-75). Other agents such as Gallium-67 have affinity for neoplasms. Another approach is to use antineoplastic agents and radioactive antibodies which will localize in the tumor. At this stage the most useful neoplasm seeking agents are Gallium-67 citrate and 111In-Bleomycin, even though infections can give false positives. The possibility should be considered of enhancing the uptake of radionuclides by neoplastic cells using increased O2 concentration.
 ...
PMID:Neoplasm localization with radionuclides. 9 47

An overview of brain metastasis with respect to the pathological, diagnostic, and therapeutic aspects is presented. Management is almost always palliative, with cure being a rare exception. Evaluation of various therapeutic modalities--radiation, chemotherapy, or surgery--has been confounded by a lack of controlled, randomized studies whereby the relative benefit of the respective modalities can be assessed objectively. Despite these limitations, some progress is being made in the identification of those patients for whom therapy is likely to be of benefit. Apart from the use of steroids to control cerebral edema, radiotherapy is currently the most commonly employed therapeutic modality for cerebral metastasis. It is the treatment of choice for multiple intracranial metastases and it affords temporary improvement in neurological symptoms in about 60% of patients. For solitary metastases, combined therapy--surgical excision followed by whole brain radiotherapy--has been shown to result in a better quality and longer duration of survival than either modality alone. Except for patients who are terminally ill, aggressive treatment seems warranted, inasmuch as therapeutic results have been improving steadily over the years. Neither chemotherapy nor immunotherapy has been shown to be of benefit in the management of cerebral metastasis. An exception is choriocarcinoma, which responds well to a combination of radiation therapy and chemotherapy. Although the prognosis for meningeal carcinomatosis is poor, improved survival may be achieved by a combination of chemotherapy and radiotherapy. These are recommended guidelines for surgical intervention, usually followed by radiotherapy: (a) In general, surgical excision is recommended only for patients with relatively superficial, solitary lesions. It is reasonable, however, to consider the excision of a metastatic lesion that is immediately life-threatening or incapacitating, even though one or more other metastatic brain lesions may be present. This may be extended to the removal of multiple metastatic brain tumors if they are surgically accessible. (b) The second consideration is whether the primary tumor can or has been treated or if the primary tumor will permit reasonably long survival. (c) There should not be metastases elsewhere in the body, although their presence should not categorically exclude the patient as a surgical candidate. (d) The patient's general condition should be satisfactory. (e) Operation is recommended if the diagnosis of the intracranial lesion is uncertain. (f) A shunt should be considered for treatment of hydrocephalus secondary to obstruction of the cerebrospinal fluid pathway by tumor or edema. (Neurosurgery, 5: 617--631, 1979).
 ...
PMID:Brain metastasis: current status and recommended guidelines for management. 9 55

Primary intracranila choriocarcinoma, either alone or with malignant teratoma, is a rare tumor. The 22 reported cases of primary intracranila mixed choriocarcinoma and malignant teratoma are reviewed, and a further case is added. This 4 1/2-year-old girl presented with multiple cranial nerve palsies, panhypopituitarism and markedly elevated blood and urine human chorionic gonadotrophin (HCG) titres. After subtotal removal of the suprasellar tumor, supervoltage radiation was given with a remarkably rapid and complete response. She died 14 months after diagnosis with no evidence of local recurrence nor of distant metastases.
 ...
PMID:Primary intracranial mixed choriocarcinoma and malignant teratoma. 9 20

Nineteen postmenopausal patients with metastatic breast cancer refractory to conventional combination chemotherapy were treated with monthly cycles with the combinations of vinblastine, adriamycin, thiotepa and halotestin. Ten patients (52%) responded with a greater than 50% regression of measurable tumor. The median duration of response was 11.5 months, with 5/10 patients still responding at a mean follow-up of 10 months. Only 2/10 responders have died with a mean follow-up of 13.8 months. In contrast, 8/9 nonresponders have died (median survival 6.0 months). Response to therapy was neither influenced by site of disease, time interval from diagnosis to primary chemotherapy nor duration of response to primary chemotherapy. No patient was hospitalized because of drug induced toxicity. This combination of drugs is a tolerable effective regimen for patients relapsing after adjuvant chemotherapy or after primary combination chemotherapy for grossly metastatic disease.
 ...
PMID:Vinblastine, adriamycin, thiotepa, and halotestin (VATH): therapy for advanced breast cancer refractory to prior chemotherapy. 10 10


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>